NASDAQ · NRIX
Nurix Therapeutics, Inc.
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
Loading market information…
NASDAQ · ZYME · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Zymeworks Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.39% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Zymeworks Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of $2.27. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Zymeworks Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 8, 2025 |
| -$0.30+33.33% vs estimate |
| $27.11M+50.42% vs estimate |
| Q4 2024 | Mar 5, 2025 | -$0.31-3,200.0% vs estimate | $31.03M+104.15% vs estimate |
|---|
| Q3 2024 | Oct 31, 2024 | -$0.39+2.5% vs estimate | $16.00M-66.01% vs estimate |
|---|
THE ANALYST VIEW
22 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $43.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$27.12-$0.14 (-0.51%)
Nurix Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.93% below the high.
$29.89+$0.23 (+0.78%)
Celldex Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.78% below the high.
$29.21-$0.78 (-2.6%)
Xencor, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.07% below the high.
$18.29-$0.47 (-2.51%)
Immunome, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.16% below the high.
$14.07+$0.57 (+4.22%)
Crescent Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.67% below the high.
$2.29-$0.07 (-2.97%)
CytomX Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.11% below the high.
$2.04+$0.03 (+1.49%)
Compugen Ltd.’s quoted price sits in the lower half of its reported 52-week range, 37.04% below the high.
$1.49-$0.13 (-8.02%)
ADC Therapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 70.08% below the high.
